CDEK
← All drugs Report issue

mupirocin

Trade name: bactroban

Small moleculeapproved

Approved

Dec 31, 1987

Mupirocin (BACTROBAN®) is an antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing. Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyltransfer RNA (tRNA) synthetase. It also severely inhibits RNA synthesis. DNA and cell wall peptidoglycan synthesis are inhibited to a lesser extent and interference with these processes is considered to be a secondary effect. Mupirocin is bactericidal at concentrations achieved by topical administration. — NCATS

Clinical trial activity

76 trials · 118 clinical orgs · 11 marketing orgs

Phase 1
6
Phase 2
18
Phase 3
10
Phase 4
24

Earliest trial started Nov 1, 2002 (NCT00156377)

Timeline

1980s

  1. Dec 31, 1987

    GlaxoSmithKline — Earliest FDA Approval

  2. Dec 31, 1987

    GlaxoSmithKline — NDA Organization

  3. Dec 31, 1987

    GlaxoSmithKline — NDA Secondary Org

2000s

  1. Dec 4, 2002

    Perrigo — NDA Secondary Org

  2. Dec 4, 2002

    Padagis Us — NDA Secondary Org

  3. Nov 7, 2003

    Perrigo — Marketing Organization

  4. Nov 7, 2003

    Teva — Marketing Organization

  5. Nov 7, 2003

    Padagis Us — Marketing Organization

  6. Sep 23, 2005

    Taro Pharmaceuticals — Marketing Organization

  7. Nov 30, 2005

    Fougera — Marketing Organization

  8. Jan 1, 2007

    Earliest Phase 3 Sponsor(trial)

  9. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2013

    Taro Pharmaceuticals — Earliest Phase 1 Sponsor(trial)

  2. Jan 24, 2013

    Glenmark Pharmaceuticals — Marketing Organization

2020s

  1. Apr 27, 2020

    Sun Pharmaceuticals — Marketing Organization

  2. Aug 31, 2021

    Encube Ethicals Pvt. Ltd. — Marketing Organization

  3. Nov 16, 2021

    Alembic — Marketing Organization

  4. Nov 15, 2022

    Amneal Pharmaceuticals — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedDec 31, 1987

Chemistry & pharmacology

Loading structure…

SMILES

C/C(=C\C(=O)OCCCCCCCCC(=O)[O-])C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O.C/C(=C\C(=O)OCCCCCCCCC(=O)[O-])C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O.O.O.[Ca+2]
Mol. weight
1075.35 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • 9-[(e)-4-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s,3s)-3- [(2s,3s)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl] oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid
  • 9-[(e)-4-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s,3s)-3- [(2s,3s)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl] oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid
  • bactroban
  • bactroban
  • bactroban
  • bactroban
  • brl 4910a
  • brl-4910a
  • brl-4910a
  • brl-4910f
  • brl-4910f
  • centany
  • centany
  • mupirocin
  • mupirocin
  • mupirocin
  • mupirocin
  • mupirocin
  • mupirocin
  • mupirocin
  • mupirocin
  • mupirocin
  • mupirocin
  • mupirocin
  • mupirocina
  • mupirocina
  • mupirocin calcium
  • mupirocin calcium
  • mupirocin calcium
  • mupirocin calcium
  • mupirocin calcium dihydrate
  • mupirocine
  • mupirocine
  • mupirocinum
  • mupirocinum
  • mupricin
  • pseudomonic acid
  • pseudomonic acid
  • pseudomonic acid
  • pseudomonic acid
  • pseudomonic acid a
  • pseudomonic acid a
  • td1414
  • turixin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06712433Phase 2Jan 31, 2025University of Pittsburgh
NCT06633588Phase 4Nov 18, 2024Swiss Paraplegic Centre Nottwil
NCT06541145N/AAug 21, 2024Bristol-Myers Squibb, Duke University
NCT06368856Phase 1Feb 29, 2024University of Lyon
NCT07064161N/AJan 29, 2024University of Santo Tomas
NCT05893810Phase 3Jun 1, 2023Jiangxi Provincial Cancer Hospital
NCT06046937Early Phase 1 (Phase 1)Jun 1, 2023Victoriano Luna Medical Center
NCT05874219Phase 2/Phase 3 (Phase 3)Apr 10, 2023Future University in Egypt
NCT07142408Phase 3Mar 13, 2023Baylor University, Temple University, The Cleveland Clinic, University of California, Davis, University of Georgia, Washington University in St. Louis
NCT05586776Phase 4Jan 31, 2023University of California, Davis, University of California, Irvine, University of California, San Francisco, University of Massachusetts
NCT05839158N/AMar 1, 2022Southern Medical University
NCT05251584N/ADec 1, 2021Government of Thailand, Silpakorn University
NCT04134676Phase 1Nov 30, 2019PT. Pharma Metric Labs, Stem Cell and Cancer Institute, Sukma Skin Treatment, Tarumanagara University
NCT04047914N/ANov 1, 2019University of Nove de Julho
NCT04155203Phase 3Oct 15, 2019Perrigo
NCT03883828Phase 2/Phase 3 (Phase 3)Apr 1, 2019Yeshiva University
NCT03962907Phase 4Jan 1, 2019Lindenhof AG
NCT03673956Phase 1/Phase 2 (Phase 2)Sep 26, 2018Mayo Clinic
NCT03489629Phase 2Apr 3, 2018Cook Children's Medical Center, Indiana University, The University of Texas, Dallas, University of Colorado, Denver, University of Michigan, University of North Carolina at Chapel Hill, University of Washington, Washington University in St. Louis
NCT03173053N/AAug 1, 2017Aalborg University, Radboud University, Sponsor GmbH, University of Amsterdam, University of Copenhagen, ZonMw: The Netherlands Organisation for Health Research and Development
Showing 20 of 76 trials
Page 1 / 4

Organizations

Research & Development (118)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Washington University in St. LouisAcademic/Hospital7442007
Department of Veteran AffairsGovernment4322005
University of California, IrvineAcademic/Hospital4222009
GlaxoSmithKlineFor profit3022002
Johns Hopkins UniversityAcademic/Hospital3332012
National Institute of Allergy and Infectious Diseases (NIAID)Government3132003
University of MichiganAcademic/Hospital3022005
Baylor UniversityAcademic/Hospital2022011
Centers for Disease Control and Prevention (CDC)Government2022009
Cook Children's Medical CenterAcademic/Hospital2012011
Department of Health and Human ServicesGovernment2012009
Harvard UniversityAcademic/Hospital2222009
Horizon Health NetworkAcademic/Hospital2222008
Hospital Corporation of AmericaAcademic/Hospital2022009
Leo PharmaFor profit2212008
Lindenhof AGFor profit2222015
Society for Pediatric DermatologyAcademic/Hospital2022005
The University of Texas, DallasAcademic/Hospital2012011
United States ArmyGovernment2112005
University of California, DavisAcademic/Hospital2022023
118 organizations
Page 1 / 6

Marketing (18)

OrganizationOrg typeRelationshipDate
AlembicFor profitSYNNov 16, 2021
AlembicFor profitMKTGNov 16, 2021
Amneal PharmaceuticalsFor profitMKTGNov 15, 2022
Encube Ethicals Pvt. Ltd.For profitMKTGAug 31, 2021
FougeraFor profitMKTGNov 30, 2005
GlaxoSmithKlineFor profitNDADec 31, 1987
GlaxoSmithKlineFor profitNDA2Dec 31, 1987
Glenmark PharmaceuticalsFor profitSYNJun 8, 2011
Glenmark PharmaceuticalsFor profitMKTGJan 24, 2013
Padagis UsFor profitMKTGNov 7, 2003
Padagis UsFor profitMKTGDec 4, 2002
Padagis UsFor profitNDA2Dec 4, 2002
PerrigoFor profitMKTGNov 7, 2003
PerrigoFor profitNDA2Dec 4, 2002
Sun PharmaceuticalsFor profitMKTGApr 27, 2020
Taro PharmaceuticalsFor profitSYNApr 27, 2020
Taro PharmaceuticalsFor profitMKTGSep 23, 2005
TevaFor profitMKTGNov 7, 2003